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Abstract
Introduction: American tegumentary leishmaniasis (ATL) and leprosy share common areas of prevalence, but reports of 
coinfection are scarce. Methods: We report a series of 9 ATL-leprosy cases and discuss the association. An integrative diagram 
to analyze the clinico-immunological features of coinfection with both diseases. Results: Nine patients with leishmaniasis (5 
cutaneous, 3 mucocutaneous, 1 disseminated case) exhibited concurrent infection with distinct clinical forms of leprosy. Our 
diagram-based analysis evidenced a divergent clinico-immunological spectrum for each disease in 8 out of 9 cases. Conclusions: 
The spectrum of ATL-leprosy comorbidity suggests that the host has a specific immune response against each pathogen.
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American tegumentary leishmaniasis (ATL) and leprosy 
remain the major neglected diseases in some developing 
countries1,2. Leishmaniasis encompasses a spectrum of vector-
borne parasitic infections caused by protozoa belonging 
to the genus Leishmania, which is represented mainly by 
the species Leishmania (Leishmania) amazonensis and 
Leishmania (Viannia) braziliensis, in Brazil1. ATL caused by 
L. (V.) braziliensis initiates as a single skin ulcer or as multiple 
skin ulcers that can be followed by mucosal involvement months 
or years later1. Leprosy is a chronic infectious disease caused by 
the non-cultivable bacillus Mycobacterium leprae that affects 
the skin and peripheral nerves2. Both diseases have become 
important public health concerns due to their wide geographic 
distribution, high incidence rates, and clinical manifestations 
with subsequent permanent serious injuries and mutilations1,2. 
ATL and leprosy are endemic to Brazil, where most of the new 
cases in the Americas emerge1,2.
Although both diseases are prevalent in some countries, 
reports on comorbidity in the same patient are scarce. 
In 1978, 8 patients with coinfections of leprosy and cutaneous 
leishmaniasis (CL) were reported in Ethiopia3, followed 
by reports of ATL-leprosy concurrence in Venezuela4, 
India5,6, Northeastern Brazil7, Southeastern Brazil8-12, and 
Central America13. 
ATL and leprosy share some intriguing features, as both are 
caused by obligate intracellular organisms and characterized by 
a spectrum of clinico-immunological manifestations that depend 
on T-cell-mediated immunity14,15. Intracellular pathogens such as 
M. leprae and Leishmania spp. can be effectively controlled by 
the Th1 CD4+ subpopulation of the T-cell response. The immune 
hyperergic pole of both ATL and leprosy is characterized 
by a strong macrophage activation stimulated mainly by 
interferon (IFN)-γ and interleukin (IL)-2. Clinically, the Th1 
pole of leprosy is represented by the paucibacillary (PB) forms 
indeterminate (I), tuberculoid (TT), and borderline-tuberculoid 
(BT) of the Ridley–Jopling classification2, and that of ATL by the 
mucocutaneous leishmaniasis (ML) form1. These clinical forms 
typically show a strong reaction in the intradermal lepromin 
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(or Mitsuda) test and the leishmanin (or Montenegro) test, 
respectively. Furthermore, the anergic pole is characterized by a 
depressed specific T-cell response with Th2 pole predominance. 
This pole is represented by the multibacillary (MB) clinical 
forms of leprosy, borderline–borderline (BB), borderline-
lepromatous (BL), and lepromatous leprosy (LL), and by the 
diffuse anergic cutaneous form of leishmaniasis (CL) caused by 
L. (L.) amazonensis or the disseminated form (DL) caused by 
L. (V.) braziliensis infection14,15. Although ATL-leprosy coinfection 
in an immunocompetent patient is still a rare occurrence, it is a 
comorbidity of growing concern. The specific immune response 
to one disease seems to influence the clinical picture of the other, 
which explains the unpredictable course and difficult management 
of both infections occurring in the same patient10.
We aimed to report a case series of ATL-leprosy coinfections 
on the basis of an integrative diagram that emphasizes the 
clinico-laboratory features to establish a possible Th1/Th2 
immunological spectrum relationship between these infectious 
diseases. 
Diagnoses of ATL and leprosy were confirmed on the basis 
of the World Health Organization recommendations1,2. For 
ATL diagnosis, exclusive skin involvement was defined as the 
CL form, whereas lesions affecting the skin and mucosa or 
just the mucosa were classified as the ML form. Patients with 
10 or more pleomorphic lesions in 2 or more body parts were 
classified as having DL. The Ridley–Joplin classification was 
used to determine the clinical form of leprosy2. Leishmanin1 
and lepromin2 intradermal tests were performed to assess the 
cellular immune response. Enzyme-linked immunosorbent assay 
(ELISA) with an anti-phenolic glycolipid 1 (PGL1) antibody 
was conducted to measure the humoral response associated 
with leprosy2. Patients were negative for HIV and hepatitis B 
and C serology, except for case 9 who was positive for hepatitis 
C. ATL diagnosis was confirmed by polymerase chain reaction 
(PCR) using primers (forward: based on a minicircle kDNA 
from the Leishmania sp. 120-bp sequence 5'-(G/C)(G/C)
(C/G)CC(A/C)CTAT(A/T)TTACACCCAACCCC-3', reverse: 
5'-GGGGAGGGGCGTTCTGCGAA-3') based on the sequence 
of a minicircle kDNA of Leishmania spp rendering a 120-bp 
PCR product. The ATL subgenus Viannia was identified by 
consecutive digestion of the PCR product with the restriction 
enzymes HaeIII and BsrI. Leprosy was diagnosed by PCR with 
primers targeting a 336-bp sequence of the M. leprae gene MntH 
(forward: 5'-CGGCTTCACGTCCAGTTTCTTC-3', reverse: 
5'-TAAGTGCCCTCGATGTAAGCGG-3'). 
Based on the clinico-immunological spectra of ATL and 
leprosy described in the literature14,15, we generated an integrative 
figure to identify overlaps between the clinical forms of ATL and 
leprosy in terms of immunological spectrum and intradermal 
tests (cellular immune response), serology (humoral response), 
and histopathology (presence or absence of pathogen)14,15. This 
diagram served to clarify and compare the association between 
both diseases in this case report series (Figure 1A). 
The 9 cases were also presented based on their clinical, 
laboratory, and immunological spectra to identify associations 
between both diseases (Figure 1B). Tables 1 and 2 summarize 
the demographical, clinical, and laboratory features of each 
patient. 
In 3 cases (patients 4, 8, and 9) the subgenera L. Viannia and 
M. leprae were simultaneously identified by PCR in the same skin 
or mucosa sample. Three patients (cases 1, 2, and 6) were initially 
diagnosed with ATL, were treated and cured, and presented 
again later with clinical features of leprosy. In the remaining 
3 patients, the order of disease manifestation was opposite: they 
first presented with leprosy and later exhibited clinical features 
of ATL during or after leprosy treatment (cases 3, 5, and 7).
ATL and leprosy share a clinico-immunological spectrum 
ranging from a strong T-cell response to a predominant B-cell 
response14,15, but we are the first to compare the spectra of both 
diseases in a case series. 
Concurrent ATL and leprosy have previously been 
reported3-5,12. Initial MB leprosy manifestation followed by 
clinical ML several years later has also been described10. Both 
ML and MB leprosy cause latent infections and sometimes 
decades elapse before these diseases become clinically 
recognizable14,15, which complicates determination of the time 
of infection and concomitant manifestation. 
The delay in clinical manifestations may also reflect lack 
of adhesion to treatment of one or both diseases7. Case 4 was 
treated with irregular multidrug therapy for leprosy for 1 year 
following clinical manifestation of ML, making it practically 
impossible to determine which disease was contracted first due 
to the long latency of both diseases. A case series in Ethiopia3 
identified patients that presented with leprosy for 2 to 7 years 
before clinical manifestation of CL. Nevertheless, an exact 
comparison with our study is difficult because L. (L.) tropica was 
the causative pathogen in these patients. Likewise, comorbidity 
of leishmaniasis with the BL clinical leprosy form5 and TT 
leprosy6 has been reported in India. Nevertheless, the anergic 
pole was attributed to the Leishmania spp. complex. 
The subgenus L. Viannia was identified in a patient with 
LL in Venezuela that also showed CL association 5 years after 
leprosy was diagnosed4. In 2002, Goulart et al.8 reported the first 
association between ATL caused by the subgenus L. Viannia 
and leprosy in Southeastern Brazil. Interestingly, this patient 
presented with the BL leprosy form with septal obstruction and 
was diagnosed with ML 3 years later8, a pattern resembling the 
time-lapse observed in our case 4. Since then, 8 cases have been 
reported in the state of Maranhão in Northeastern Brazil, 7 of 
which experienced BB-CL comorbidity and 1 CL associated 
with indeterminate leprosy7. 
Genetic variations have been related to infectivity and 
pathogenicity of Leishmania. Certain L. (V.) braziliensis strains 
were proposed as causative pathogens for DL which is an 
emerging in Brazil but has never been reported as a coinfection 
with leprosy (patient 9). The concomitant chronic hepatitis C 
infection of this patient may have increased the susceptibility 
to ATL and leprosy coinfection.
ML is allocated to the maximum resistance pole of the Th1 
immune profile. This exacerbated immune response accounts for 
local mucous destruction14. The immune response of ML patients 
did not resemble the immune spectrum of leprosy in this study10 
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FIGURE 1. (A) Clinical and immunological spectra of American tegumentary leishmaniasis and leprosy and placement of the reported 9 cases within the 
proposed spectra. (B) Clinical laboratory features of each patient according to the clinical spectrum for leprosy and American tegumentary leishmaniasis. 
BB: borderline-borderline, BL: borderline-lepromatous, BT: borderline-tuberculoid, CL: cutaneous leishmaniasis, DL: disseminated leishmaniasis, 
LL: lepromatous leprosy, ML: mucocutaneous leishmaniasis, N.D.: not determined, PGL: phenolic glycolipid 1, TT: tuberculoid leprosy.
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TABLE 1: Clinical and immunological features of the initially diagnosed disease of 9 patients with American tegumentary leishmaniasis and leprosy in 
Southeastern Brazil.




Initial tests InitialTreatment Diagnosis
1 53 M Farmer Malar ulcer 5
LST +
Amastigotes -
PCR (L. Viannia 
complex) +
MA CL










4 64 M Farmer
LL (treated in primary health 
post). Squeals such as atrophy 
of interosseous hand muscles 




Bacilloscopy –* MDT LL
5 54 M Retired
Diffuse infiltrated erythematous 








6 22 F Student Skin ulcers on the right forearm and left malar region 36
LST +
Amastigotes - MA CL
7 66 M Janitor
Sensitivity reduced on the 
dorsum of the left foot and 






8 84 M Farmer Nasal septum ulcer -
LST +
Amastigotes -
PCR (L. Viannia 
complex) +
MA (irregular) ML
9 58 M Retired Sensitivity reduced on the dorsum 60
LST –
Anti-PGL1 –
Bacilloscopy – MDT (irregular) BB
AFB: acid-fast bacilli; BB: borderline-borderline; BL: borderline lepromatous; BT: borderline tuberculoid; CL: cutaneous leishmaniasis; DL: disseminated 
leishmaniasis; F: female; LL: lepromatous leprosy; LST: leishmanin skin test; M: male; MA: meglumine antimoniate; MDT: multidrug therapy; 
ML: mucocutaneous leishmaniasis; PCR: polymerase chain reaction; PGL1: phenolic glycolipid 1; TT: tuberculoid leprosy; +: positive test result; –: negative 
test result; ±: weak reaction in the test; *: post-treatment.
(Figure 1). For example, case 2 presented with the LL form in 
the anergic pole, and high levels of anti-PGL1 antibodies and 
presence of bacillus-forming globias in the skin confirmed the 
Th2 immune pattern and consequently deficient macrophage 
activity in this patient. Nevertheless, the patient exhibited the 
ML hyperergic pole representing ATL with granulomatous 
infiltrate and the amastigote form of Leishmania spp. was still 
present in the histopathological exam. Case 4 also presented 
with ML with no evidence of previous cutaneous ulcers but 
with concurrence of the LL clinical form. 
The complex interaction between the parasite and the 
immune response of the host may complicate the interpretation 
of the ATL spectrum. ML induces a strong Th1 response 
resulting in a granulomatous immune response. Nonetheless, 
ML usually results from previous CL that disseminated to 
the mucosa via the blood or lymphatic system, a process that 
is probably attributed to failure in the local cellular immune 
response10. Thus, it appears that ML should not be placed within 
the spectral pole of a strong T-cell immune response. 
The fact that the immune response of the host to each of the 
pathogens may alter the course of the other disease may lead 
to a clinical picture that differs from that expected for each 
disease alone, and physicians should be aware that the diagnosis 
of coinfection could be challenging. Azeredo-Coutinho 
et al.10 reported a case of LL with an IL-10-mediated regulatory 
response controlling the ML immunopathology, which may 
explain the opposing spectral Th1/Th2 poles for leprosy and 
ATL observed in cases 2 and 4. Moreover, the genetic profile 
of the host should be carefully analyzed to identify specific 
predispositions for ATL and leprosy that possibly explain the 
infrequent occurrence of both diseases in the same patient.
To our knowledge, this is the first study proposing a 
comparison between the clinical and laboratory features of ATL 
and leprosy based on the Th1/Th2 immunological spectrum. 
The diagram shown here could prove useful to researchers and 
physicians working in areas where leprosy and leishmaniasis 
are prevalent (Figure 1A). 
Due to the retrospective character of this case series, the 
genetic background of the patients and certain other parameters 
such as the immunological profile (e.g., cytokines) and 
intercurrences during disease progression were not analyzed. 
Nonetheless, we described important immunological tests and 
clinical features, allowing us to conduct a clinico-immunological 
comparison of both diseases in 9 patients. 
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Secondary clinical presentation Secondary test Diagnosis








Facial infiltration, cilia loss, generalized 






3 60 Ulcer in the left knee
LST +
Amastigotes -




(Still under MDT for 
leprosy)
Friable granulomatous vegetative nasal lesion
LST+
Amastigotes –
PCR (L. Viannia complex) +
PCR (M. leprae) +
ML
5 24 Trunk ulcer
LST +
Amastigotes -
PCR (L. Viannia complex) +
PCR (M. leprae) +
CL




PCR (M. leprae) +
TT
7 18 Ulcer on the right forearm
LST +
Amastigotes -
PCR (L. Viannia complex) +
CL
8 120
Erythematous macule in the right thigh 





PCR (M. leprae) +
TT
9 120 10 ulcers on the posterior region of the neck, in the left arm, and in the trunk
LST –
Amastigotes +
PCR (L. Viannia complex) +
PCR (M. leprae) +
DL
AFB: acid-fast bacilli; BB: borderline-borderline; BL: borderline lepromatous; BT: borderline tuberculoid; CL: cutaneous leishmaniasis; DL: disseminated 
leishmaniasis; LL: lepromatous leprosy; LST: leishmanin skin test; MA: meglumine antimoniate; MDT: multidrug therapy; ML: mucocutaneous leishmaniasis; 
PCR: polymerase chain reaction; PGL1: phenolic glycolipid 1; TT: tuberculoid leprosy;  +: positive test result; –: negative test result; ±: weak reaction in 
the test; *: post-treatment.
The cases described herein included patients that were 
particularly susceptible to a coinfection with ATL and leprosy 
because they live in an area where both diseases are endemic. 
Although epidemiological susceptibility is probably the 
most important risk factor for contracting both diseases, 
immunological and genetic conditions that favor a coinfection 
cannot be excluded. 
The present study has shown no correlation between the 
Th1/Th2 immunological spectra of the clinical forms of ATL 
and leprosy in this case series, which suggests a specific host 
immune response against each pathogen. Increasing incidence 
rates of ATL and leprosy concurrence must be acknowledged to 
improve diagnostic and therapeutic strategies in regions where 
both diseases are prevalent. 
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